<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03563144</url>
  </required_header>
  <id_info>
    <org_study_id>QUILT-3.088</org_study_id>
    <nct_id>NCT03563144</nct_id>
  </id_info>
  <brief_title>QUILT-3.088: NANT Pancreatic Cancer Vaccine</brief_title>
  <official_title>QUILT-3.088 NANT Pancreatic Cancer Vaccine: Phase II Randomized Trial of the NANT Pancreatic Cancer Vaccine vs. Standard-of-Care as First- Line Treatment for Patients With Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunityBio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmunityBio, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      QUILT-3.088 NANT Pancreatic Cancer Vaccine: Phase II Randomized Trial of the NANT Pancreatic&#xD;
      Cancer Vaccine vs. Standard-of-Care as First- Line Treatment for Patients with Metastatic&#xD;
      Pancreatic Cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two-cohort, open-label, randomized phase 2 study to evaluate the safety and&#xD;
      efficacy (as assessed by PFS) of the NANT Pancreatic Cancer Vaccine regimen (experimental&#xD;
      arms) vs SoC therapy (control arms) as first-line treatment for subjects with metastatic&#xD;
      pancreatic cancer.&#xD;
&#xD;
      Subjects will be enrolled into two independent cohorts based on ECOG status. Subjects with&#xD;
      ECOG 0-1 will be randomized 1:1 to receive the NANT Pancreatic Cancer Vaccine regimen&#xD;
      (experimental arm) or gemcitabine in combination with nab-paclitaxel (control arm), while&#xD;
      subjects with ECOG 2 will be randomized 1:1 to receive the NANT Pancreatic Cancer Vaccine&#xD;
      regimen (experimental arm) or gemcitabine monotherapy (control arm).&#xD;
&#xD;
      The experimental arms will be administered in two phases, an induction and a subsequent&#xD;
      maintenance phase. The treatment regimen administered in the experimental arms will be&#xD;
      identical for all subjects, independent of ECOG status. Subjects may continue induction&#xD;
      treatment for up to 1 year. Those who have a complete response (CR) in the induction phase&#xD;
      will enter the maintenance phase of the study. Subjects who experience ongoing stable disease&#xD;
      (SD) or an ongoing partial response (PR) after 1 year of induction phase treatment may enter&#xD;
      the maintenance phase at the Investigator's discretion. Subjects may remain on the&#xD;
      maintenance phase of the study for up to 1 year.&#xD;
&#xD;
      Treatment in the study will be discontinued if the subject experiences confirmed PD or&#xD;
      unacceptable toxicity, withdraws consent, or if the Investigator feels it is no longer in the&#xD;
      subject's best interest to continue treatment. Subjects receiving treatment in the control&#xD;
      arms may cross over to treatment in the induction phase of the experimental arms after&#xD;
      experiencing PD. Subjects receiving treatment in the experimental arms with an initial&#xD;
      assessment of PD per RECIST 1.1 may, at the discretion of the Investigator, continue to&#xD;
      receive study treatment until PD is confirmed. The maximum time on study treatment is 2&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Trial not initiated&#xD;
  </why_stopped>
  <start_date type="Anticipated">August 2018</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a randomized parallel group study comparing the NANT Pancreatic Cancer Vaccine and standard therapy with respect to efficacy and safety in treatment na√Øve patients with pancreatic cancer. Patients will be stratified by ECOG status and then randomized 1:1 to receive either the NANT Pancreatic Vaccine (n~532) or standard therapy with gemcitabine alone (ECOG 2; n~266) or combined with nab-paclitaxel (ECOG 0-1; n~266). Treatment may continue for up to 2 years or until documented progression (RECIST v 1.1) or unacceptable toxicity. Patients on standard therapy who progress or experience unacceptable toxicity may crossover to receive NANT Pancreatic Vaccine.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>12 mths</time_frame>
    <description>Compare the efficacy of the NANT Pancreatic Cancer Vaccine regimen vs standard-of-care (SoC) therapy as first-line treatment for patients with metastatic pancreatic cancer as assessed by progression-free survival (PFS) using RECIST Version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>24 months</time_frame>
    <description>Overall Survival from first treatment to date of death (any cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>19 months</time_frame>
    <description>Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete response per RECIST 1.1 and irRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>19 months</time_frame>
    <description>Duration of Response from date of first response to date of disease progression or death (any cause), per RECIST 1.1 and irRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>19 months</time_frame>
    <description>Disease Control Rate: the number of patients with a CR, PR or SD lasting at least 2 months per RECIST 1.1 and irRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life by Patient-Reported Outcomes</measure>
    <time_frame>19 months</time_frame>
    <description>Quality of Life as assessed by Patient Reported Outcomes using the FACT-C questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>12 months</time_frame>
    <description>Progression Free Survival from baseline to progression per irRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of safety as determined by incidence or treatment-emergent adverse events</measure>
    <time_frame>19 months</time_frame>
    <description>Incidence of treatment -emergent adverse events using NCI CTCAE Version 4.03</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>in subjects with ECOG=2 or subjects with ECOG=0 or 1&#xD;
A combination of agents will be administered to subjects in this study:&#xD;
cyclophosphamide, bevacizumab, oxaliplatin, capecitabine, 5-fluorouracil, leucovorin, nab-paclitaxel, aldoxorubicin HCl, avelumab, ALT-803, haNK, GI-4000, GI-6207, GI-6301, ETBX-011, ETBX-021, ETBX-051, ETBX-061.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine and Nab-paclitaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine plus Nab-paclitaxel will be administered to subjects with ECOG=2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine will be administered to subjects with ECOG=0 or 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine is a type of chemotherapy medication used to interfere with the cancer cells' ability to grow and divide.</description>
    <arm_group_label>Gemcitabine</arm_group_label>
    <arm_group_label>Gemcitabine and Nab-paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>NAB-paclitaxel is a type of chemotherapy called a microtubule inhibitor. Microtubule inhibitors interfere with a cancer cell's ability to grow and divide.</description>
    <arm_group_label>Gemcitabine and Nab-paclitaxel</arm_group_label>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aldoxorubicin HCl</intervention_name>
    <description>Albumin-binding prodrug of doxorubicin HCl</description>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALT-803</intervention_name>
    <description>Recombinant human super agonist interleukin-15 (IL-15) complex</description>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-011</intervention_name>
    <description>Ad5 [E1-, E2b-]-CEA</description>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-021</intervention_name>
    <description>Ad5 [E1-, E2b-]-human epidermal growth factor receptor 2 [HER2] vaccine</description>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-051</intervention_name>
    <description>Ad5 [E1-, E2b-]-Brachyury vaccine</description>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-061</intervention_name>
    <description>Ad5 [E1-, E2b-]-mucin 1[MUC1]</description>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI-4000</intervention_name>
    <description>Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins</description>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI-6207</intervention_name>
    <description>CEA yeast vaccine</description>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI-6301</intervention_name>
    <description>Brachyury yeast vaccine</description>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>haNK</intervention_name>
    <description>NK-92 [CD16.158V, ER IL-2]</description>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Avelumab</description>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab</description>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine</description>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate</description>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>5-fluoro-2,4 (1H,3H)-pyrimidinedione</description>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt</description>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin</description>
    <arm_group_label>NANT Pancreatic Cancer Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ‚â• 18 years old.&#xD;
&#xD;
          2. Able to understand and provide a signed informed consent that fulfills the relevant&#xD;
             IRB or Independent Ethics Committee (IEC) guidelines.&#xD;
&#xD;
          3. Histologically-confirmed metastatic pancreatic adenocarcinoma that has not been&#xD;
             previously treated with chemotherapy.&#xD;
&#xD;
          4. ECOG performance status of 0-2.&#xD;
&#xD;
          5. Have at least 1 measurable lesion of ‚â• 1.0 cm.&#xD;
&#xD;
          6. If available, must be willing to release a recent formalin-fixed, paraffin-embedded&#xD;
             (FFPE) tumor biopsy specimen for prospective and exploratory tumor molecular&#xD;
             profiling. If an historic specimen is not available, the subject must be willing to&#xD;
             undergo a biopsy during the screening period, if considered safe by the Investigator.&#xD;
&#xD;
          7. Must be willing to provide blood samples prior to the start of treatment on this study&#xD;
             for prospective tumor molecular profiling and exploratory analyses.&#xD;
&#xD;
          8. Must be willing to provide a tumor biopsy specimen 8 weeks after the start of&#xD;
             treatment for exploratory analyses, if considered safe by the Investigator.&#xD;
&#xD;
          9. Ability to attend required study visits and return for adequate follow-up, as required&#xD;
             by this protocol.&#xD;
&#xD;
         10. Agreement to practice effective contraception for female subjects of child-bearing&#xD;
             potential and non-sterile males. Female subjects of child-bearing potential must agree&#xD;
             to use effective contraception for up to 1 year after completion of therapy, and&#xD;
             non-sterile male subjects must agree to use a condom for up to 4 months after&#xD;
             treatment. Effective contraception includes surgical sterilization (eg, vasectomy,&#xD;
             tubal ligation), two forms of barrier methods (eg, condom, diaphragm) used with&#xD;
             spermicide, intrauterine devices (IUDs), and abstinence.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serious uncontrolled concomitant disease that would contraindicate the use of the&#xD;
             investigational drug used in this study or that would put the subject at high risk for&#xD;
             treatment-related complications.&#xD;
&#xD;
          2. Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's&#xD;
             disease, autoimmune disease associated with lymphoma).&#xD;
&#xD;
          3. History of organ transplant requiring immunosuppression.&#xD;
&#xD;
          4. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative&#xD;
             colitis).&#xD;
&#xD;
          5. Inadequate organ function, evidenced by the following laboratory results:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) &lt; 1,000 cells/mm^3.&#xD;
&#xD;
               2. Platelet count &lt; 75,000 cells/mm^3.&#xD;
&#xD;
               3. Total bilirubin greater than the upper limit of normal (ULN; unless the subject&#xD;
                  has documented Gilbert's syndrome).&#xD;
&#xD;
               4. Aspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT])&#xD;
                  &gt; 2.5 √ó ULN (&gt; 5 √ó ULN in subjects with liver metastases).&#xD;
&#xD;
               5. Alkaline phosphatase levels (ALP) &gt; 2.5 √ó ULN (&gt; 5 √ó ULN in subjects with liver&#xD;
                  metastases, or &gt;10 √ó ULN in subjects with bone metastases).&#xD;
&#xD;
               6. Serum creatinine &gt; 2.0 mg/dL or 177 Œºmol/L.&#xD;
&#xD;
               7. Serum anion gap &gt; 16 mEq/L or arterial blood with pH &lt; 7.3.&#xD;
&#xD;
               8. Medically uncorrectable grade 3 anemia (hemoglobin &lt; 8 g/dL).&#xD;
&#xD;
          6. Uncontrolled hypertension (systolic &gt; 160 mm Hg and/or diastolic &gt; 110 mm Hg) or&#xD;
             clinically significant (ie, active) cardiovascular disease, cerebrovascular&#xD;
             accident/stroke, or myocardial infarction within 6 months prior to first study&#xD;
             medication; unstable angina; congestive heart failure of New York Heart Association&#xD;
             grade 2 or higher; or serious cardiac arrhythmia requiring medication. Subjects with&#xD;
             uncontrolled hypertension should be medically managed on a stable regimen to control&#xD;
             hypertension prior to study entry.&#xD;
&#xD;
          7. Serious myocardial dysfunction defined by echocardiogram (ECHO) as absolute left&#xD;
             ventricular ejection fraction (LVEF) 10% below the institution's lower limit of&#xD;
             predicted normal.&#xD;
&#xD;
          8. Dyspnea at rest due to complications of advanced malignancy or other disease requiring&#xD;
             continuous oxygen therapy.&#xD;
&#xD;
          9. Positive results of screening test for human immunodeficiency virus (HIV).&#xD;
&#xD;
         10. Current chronic daily treatment (continuous for &gt; 3 months) with systemic&#xD;
             corticosteroids (dose equivalent to or greater than 10 mg/day methylprednisolone),&#xD;
             excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic&#xD;
             reaction or anaphylaxis in subjects who have known contrast allergies is allowed.&#xD;
&#xD;
         11. Known hypersensitivity to any component of the study medication(s).&#xD;
&#xD;
         12. Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug&#xD;
             reaction with any of the study medications.&#xD;
&#xD;
         13. Concurrent or prior use of a strong cytochrome P450 (CYP)3A4 inhibitor (including&#xD;
             ketoconazole, itraconazole, posaconazole, clarithromycin, indinavir, nefazodone,&#xD;
             nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, and grapefruit&#xD;
             products) or strong CYP3A4 inducers (including phenytoin, carbamazepine, rifampin,&#xD;
             rifabutin, rifapentin, phenobarbital, and St John's Wort) within 14 days before study&#xD;
             day 1.&#xD;
&#xD;
         14. Concurrent or prior use of a strong CYP2C8 inhibitor (gemfibrozil) or moderate CYP2C8&#xD;
             inducer (rifampin) within 14 days before study day 1.&#xD;
&#xD;
         15. History of receiving any investigational treatment for metastatic pancreatic cancer,&#xD;
             or participation in an investigational drug study within 30 days prior to screening&#xD;
             for this study, except for testosterone-lowering therapy in men with prostate cancer.&#xD;
&#xD;
         16. Assessed by the Investigator to be unable or unwilling to comply with the requirements&#xD;
             of the protocol.&#xD;
&#xD;
         17. Concurrent participation in any interventional clinical trial.&#xD;
&#xD;
         18. Pregnant and nursing women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chan Soon-Shiong Institute for Medicine</name>
      <address>
        <city>El Segundo</city>
        <state>California</state>
        <zip>90245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>June 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Avelumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

